Who Paid My Doc
Eloisa Dimayuga
Infectious Disease Daytona Beach, FL Medical Doctor
NPI 1417923889 CMS profile 290808
303 N Clyde Morris Blvd, Daytona Beach, FL 32114
General payments
$275
Research payments
$0
Ownership & investment interest
$0
Through program year 2023, Eloisa Dimayuga of Daytona Beach, FL is reported in the CMS Open Payments database as having received $275 across 3 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 42nd percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $121 | 1 | |
| 2022 | General | $125 | 1 | |
| 2019 | General | $29 | 1 |
Beside peers
- Eloisa Dimayuga
- Infectious Disease median
- Middle half of Infectious Disease
- National median
In program year 2025, general payments to Eloisa Dimayuga were reported at $0. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.
Show as a table
| Year | Eloisa Dimayuga | Infectious Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $29 | $190 | $60–$862 | $163 |
| 2020 | $0 | $124 | $32–$606 | $114 |
| 2021 | $0 | $148 | $38–$905 | $132 |
| 2022 | $125 | $166 | $50–$834 | $149 |
| 2023 | $121 | $171 | $57–$787 | $160 |
| 2024 | $0 | $176 | $52–$752 | $164 |
| 2025 | $0 | $188 | $57–$766 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 5 billing codesPaid by Medicare
$52,532
Medicare patients
206
Services billed
645
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 66% | |
| Chronic kidney disease | 61% | |
| Heart failure | 60% | |
| Ischemic heart disease | 60% | |
| Diabetes | 57% | |
| Atrial fibrillation | 56% | |
| Depression | 54% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
3 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Infectious Disease in Florida
Lennox Archibald
Infectious Disease · Gainesville, FL
Moti Ramgopal
Infectious Disease · Fort Pierce, FL
Juan Diaz
Infectious Disease · Altamonte Springs, FL
Charlotte-Paige Rolle
Infectious Disease · Orlando, FL
Kenneth Alexander
Infectious Disease · Orlando, FL
Douglas Brust
Infectious Disease · Miami, FL
Related records
Infectious Disease in Florida
Practitioners in the same specialty and state, ranked by reported value.
All Infectious Disease
Everyone recorded under this specialty, nationwide.
Doctors in Florida
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.